Alacrita and INC Research are co-hosting a thought leadership luncheon on Thursday, November 3rd at the Le Meriden Hotel in Cambridge, MA from 11:00-1:30pm for biotech/pharma companies specializing in hematology and oncology.
The lunch will feature remarks from Scott Jackson, former CEO of Celator Pharma, who will tell his story of re-formulating a compound for the treatment of AML and his partnering journey with Jazz Pharma.
The event will also include three round table discussions on the following topics:
- Seamless Designs
- Impact of Novel Developments (including Immuno -Oncology) on Investigators and Trial Participation
- “Novel” Geographies to Consider for Biotech Phase I/II Oncology Clinical Trials